Research programme: metabolic disorder therapeutics - Relburn Metabolomics

Drug Profile

Research programme: metabolic disorder therapeutics - Relburn Metabolomics

Alternative Names: RLBN 1001; RLBN 2020 series; RLBN 3010 series

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Relburn Metabolomics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Gout

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Gout in USA
  • 11 Oct 2017 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route), before October 2017
  • 11 Oct 2017 Relburn Metabolomics plans to file an IND application with the US FDA in USA for Non-alcoholic steatohepatitis and Gout
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top